TM30089 available for gb closing Feb. 8th

[John Difool]

DM me if you are interested about this compound. I am starting a gb and we will go with a limited qty.

TM30089 is a potent, selective, and orally active prostaglandin D2 receptor CRTH2 antagonist.

Previous discussions.

https://www.gourmetstylewellness.com/interact/threads/has-anyone-here-used-tm-30089-huge-half-life.111893/

https://www.researchgate.net/public...rogen_Receptors_in_Human_Dermal_Papilla_Cells

https://www.baldtruthtaIk.com/threads/22409-Why-did-Setipiprant-win-over-Ramatroban-TM30089-!

 

[fashy]

Why the revived interest for this? Seems like people explored this route in the past, some had results, many didn't.

 

[Nehel]

Stop scamming people, all your “GBs” are failures...

 

[BetaBoy]

Prostaglandin D2 as a target for Androgenetic Alopecia is a non-starter. Results from the Phase IIA (N=169) double blinded, multicenter, 32 week, clinical trial for Setipiprant released late last year showed it had zero effect on hair outcomes vs placebo.

 

[Redgate]

Stop scamming people, all your “GBs” are failures...

retard

 

[jamesbooker1975]

Prostaglandin D2 as a target for Androgenetic Alopecia is a non-starter. Results from the Phase IIA (N=169) double blinded, multicenter, 32 week, clinical trial for Setipiprant released late last year showed it had zero effect on hair outcomes vs placebo.

Prostaglandin D2 as a target for Androgenetic Alopecia is a non-starter. Results from the Phase IIA (N=169) double blinded, multicenter, 32 week, clinical trial for Setipiprant released late last year showed it had zero effect on hair outcomes vs placebo.

Well, Setipiprant actually was useless for all the clinical trials, Asthma , Allergy, etc. So wonder how good it is actually inhibiting PGD2 .

 

[John Difool]

Prostaglandin D2 as a target for Androgenetic Alopecia is a non-starter. Results from the Phase IIA (N=169) double blinded, multicenter, 32 week, clinical trial for Setipiprant released late last year showed it had zero effect on hair outcomes vs placebo.

Setipiprant is not TM. Good try.

 

[BetaBoy]

Setipiprant is not TM. Good try.

Really that's all you've got to say?! The MoA is exactly the same, do you not find it just a little concerning that a Phase IIA RCT showed zero efficacy against Androgenetic Alopecia for a Prostaglandin D2 receptor CRTH2 antagonist.

 

[BetaBoy]

Well, Setipiprant actually was useless for all the clinical trials, Asthma , Allergy, etc. So wonder how good it is actually inhibiting PGD2 .

The investigators performed scalp biopsies on a sub-sample of participants within 2 centres and confirmed that Setipiprant was in sufficient or exceeded the estimated quantities needed to affect PGD2-CRTH2 signalling within the hair follicle.

 

[jamesbooker1975]

The investigators performed scalp biopsies on a sub-sample of participants within 2 centres and confirmed that Setipiprant was in sufficient or exceeded the estimated quantities needed to affect PGD2-CRTH2 signalling within the hair follicle.

Yes. Wonder how Cetirizine works, cause it really works .
But yes, it look like the PDG2 theory is dead .

 

[John Difool]

Prostaglandin D2-Mediated DP2 and AKT Signal Regulate the Activation of Androgen Receptors in Human Dermal Papilla Cells

Prostaglandin D2 (PGD2) and prostaglandin D2 receptor 2 (DP2) is known to be an important factor in androgenetic alopecia (Androgenetic Alopecia). However, the effect of PGD2 in human dermal papilla cells (hDPCs) is not fully understood. The function of PGD2-induced expression of the androgen receptor (AR), DP2...

www.mdpi.com

 

[John Difool]

I am planning to use it at a human dosage.